Inventor · disambiguated record
Elaine M. Pinheiro
Also filed as: PINHEIRO ELAINE · PINHEIRO ELAINE M
2 granted patents·7 pending applications·3 citations·filing 2014–2022
41Inventor score
Files withMERCK SHARP & DOHME5MERCK SHARP & DOHME LLC2EISAI R&D MAN CO LTD1GLAXOSMITHKLINE IP DEV LTD1
Top patents by PatentIndex Score
9 records- 0174US10010608B2Combination therapies for cancerMERCK SHARP & DOHME·Filed 2014·Granted Jul 3, 2018·3 cites·10 claims
- 0256US11052065B2Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonistMERCK SHARP & DOHME·Filed 2018·Granted Jul 6, 2021·0 cites·11 claims
- 0350US2025064794A1A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinibEISAI R&D MAN CO LTD·Filed 2022·Application pending·0 cites
- 0449US2019298826A1Combination therapies for cancerMERCK SHARP & DOHME·Filed 2018·Application pending·0 cites
- 0546US2023250182A1Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereofMERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 0645US2023210838A1Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinibMERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 0744US2022340660A1Biomarkers for anti-tigit antibody treatmentMERCK SHARP & DOHME·Filed 2019·Application pending·0 cites
- 0839US2018044418A1Combination of a pd-1 antagonist and vorinostat for treating cancerMERCK SHARP & DOHME·Filed 2016·Application pending·0 cites
- 0932US2019023791A1Combination Treatments and Uses and Methods ThereofGLAXOSMITHKLINE IP DEV LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elaine M. Pinheiro files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →